Wells Fargo raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $49 from $48 and keeps an Overweight rating on the shares. The firm thinks X-TOLE2 is likely to be positive, and given the size of the Phase 2, Wells expects any pullback in efficacy to be small.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Highlights 2025 Results and Expands Late-Stage Pipeline
- Xenon Pharmaceuticals reports Q4 EPS ($1.31), consensus ($1.21)
- Xenon Pharmaceuticals options imply 24.8% move in share price post-earnings
- Is XENE a Buy, Before Earnings?
- Xenon Pharmaceuticals initiated with an Outperform at Wolfe Research